as a medicinal agent.

Patent Document 1: Japanese Unexamined Patent Application (Translation of PCT Application), Publication No. 2009-536918

SUMMARY OF THE DISCLOSURE

Problems to be Solved by the Disclosure

The present disclosure is made in view of the above circumstances, and an objective of the present disclosure is to provide a novel injectable agent having superior sustained-releasability of a medicinal agent.

In one aspect, there is provided an injectable agent comprising a medicinal agent, trehalose and gellan gum, wherein the content of the medicinal agent is 0.0001 to 50.00% (w/v), and the content of trehalose is 0.1 to 50.0% (w/v), and the content of gellan gum is 0.01 to 3.00 %(w/v) relative to the total volume of the injectable agent.

In another aspect, there is provided the use of an agent comprising a medicinal agent, trehalose and gellan gum in the manufacture of a medicament for delivery of said medicinal agent, said medicament being an injectable agent and is to be contacted with a body fluid, wherein the content of the medicinal agent is 0.0001 to 50.00% (w/v), and the content of trehalose is 0.1 to 50.0% (w/v), and the content of gellan gum is 0.01 to 3.00% (w/v) relative to the total volume of the injectable agent.

In another aspect, there is provided a method of forming a depot, the method comprising: exposing an injectable agent comprising a medicinal agent, trehalose and gellan gum to a pseudo-body fluid or a phosphate buffer solution, wherein the content of the medicinal agent is 0.0001 to 50.00% (w/v), and the content of trehalose is 0.1 to 50.0% (w/v), and the content of gellan gum is 0.01 to 3.00% (w/v) relative to the total volume of the injectable agent.

CLAIMS

1. An injectable agent comprising a medicinal agent, trehalose and gellan gum, wherein the content of the medicinal agent is 0.0001 to 50.00% (w/v), and the content of trehalose is 0.1 to 50.0% (w/v), and the content of gellan gum is 0.01 to 3.00% (w/v) relative to the total volume of the injectable agent.

2. The injectable agent according to claim 1, wherein the content of the medicinal agent is 0.05 to 40.00 % (w/v), and the content of trehalose is 1.0 to 20.0 % (w/v), and the content of gellan gum is 0.10 to 1.0 % (w/v) relative to the total volume of the injectable agent.

3. The injectable agent according to claim 1 or 2, wherein the injectable agent forms a depot upon exposure to a phosphate buffer solution, a body fluid, or a pseudo-body fluid.

4. The injectable agent according to any one of claims 1 to 3, wherein the injectable agent is intended for intravitreal administration.

5. Use of an agent comprising a medicinal agent, trehalose and gellan gum in the manufacture of a medicament for delivery of said medicinal agent, said medicament being an injectable agent and is to be contacted with a body fluid, wherein the content of the medicinal agent is 0.0001 to 50.00% (w/v), and the content of trehalose is 0.1 to 50.0% (w/v), and the content of gellan gum is 0.01 to 3.00% (w/v) relative to the total volume of the injectable agent.

6. A method of forming a depot, the method comprising: exposing an injectable agent comprising a medicinal agent,

trehalose and gellan gum to a pseudo-body fluid or a phosphate buffer solution, wherein the content of the medicinal agent is 0.0001 to 50.00% (w/v), and the content of trehalose is 0.1 to 50.0% (w/v), and the content of gellan gum is 0.01 to 3.00% (w/v) relative to the total volume of the injectable agent.